about
The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptorsMolecular identification of N-acetylaspartylglutamate synthase and beta-citrylglutamate synthaseAdipose tissue NAPE-PLD controls fat mass development by altering the browning process and gut microbiota.Non-invasive in vivo imaging of early metabolic tumor response to therapies targeting choline metabolism.Development and validation of an HPLC-MS method for the simultaneous quantification of key oxysterols, endocannabinoids, and ceramides: variations in metabolic syndrome.Genetic manipulation of palmitoylethanolamide production and inactivation in Saccharomyces cerevisiae.beta-Lactams derived from a carbapenem chiron are selective inhibitors of human fatty acid amide hydrolase versus human monoacylglycerol lipase.NIR-mbc94, a fluorescent ligand that binds to endogenous CB(2) receptors and is amenable to high-throughput screening.Hepatic n-3 polyunsaturated fatty acid depletion promotes steatosis and insulin resistance in mice: genomic analysis of cellular targets.Increasing antiproliferative properties of endocannabinoids in N1E-115 neuroblastoma cells through inhibition of their metabolism.The endocannabinoid system links gut microbiota to adipogenesisThe association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action.Current knowledge on the antagonists and inverse agonists of cannabinoid receptors.Chronic endocannabinoid system stimulation induces muscle macrophage and lipid accumulation in type 2 diabetic mice independently of metabolic endotoxaemiaIntestinal epithelial MyD88 is a sensor switching host metabolism towards obesity according to nutritional status.Endocannabinoids and related N-acylethanolamines in the control of appetite and energy metabolism: emergence of new molecular players.Lipid transport function is the main target of oral oleoylethanolamide to reduce adiposity in high-fat-fed miceAltered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: impact on apelin regulation in adipose tissue.Dual inhibition of alpha/beta-hydrolase domain 6 and fatty acid amide hydrolase increases endocannabinoid levels in neurons.Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant miceNon Digestible Oligosaccharides Modulate the Gut Microbiota to Control the Development of Leukemia and Associated Cachexia in Mice.Gut microbiota-derived propionate reduces cancer cell proliferation in the liverMicroglia produce and hydrolyze palmitoylethanolamide.An optimized GC-MS method detects nanomolar amounts of anandamide in mouse brain.Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis.Blocking the cannabinoid receptors: drug candidates and therapeutic promises.ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol phosphate onto α-dystroglycan.The FAAH inhibitor URB597 efficiently reduces tyrosine hydroxylase expression through CB₁- and FAAH-independent mechanisms.Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6.Inhibition of the regulator of G protein signalling RGS4 in the spinal cord decreases neuropathic hyperalgesia and restores cannabinoid CB1 receptor signalling.Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities.Endocannabinoid biosynthesis and inactivation, from simple to complex.Inhibitors of the endocannabinoid-degrading enzymes, or how to increase endocannabinoid's activity by preventing their hydrolysis.The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity.Controlling 2-arachidonoylglycerol metabolism as an anti-inflammatory strategy.COX-2-derived endocannabinoid metabolites as novel inflammatory mediators.Harnessing the anti-inflammatory potential of palmitoylethanolamide.Endocannabinoids and the Digestive Tract and Bladder in Health and Disease.N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis.Synthesis, half-wave potentials and antiproliferative activity of 1-aryl-substituted aminoisoquinolinequinones.
P50
Q24617322-5CC6E329-DD74-4DC4-ACCA-30E41BD340B1Q28506479-4AB39A17-0741-4215-BCFC-2A4264F08237Q30372594-61EDDDA0-E88C-48ED-BB5B-5ABEE62E3C42Q31027315-7D19CDF8-0EFE-488C-A005-E1ACAAB48A82Q33466544-64F68F1A-EC6F-481A-9E7D-344D543621F2Q33468429-127E7B44-A628-45DF-A51C-953149BF1689Q33514045-C698A2A4-52CB-42E3-A969-7D5805349C1CQ33910732-38F7BAA2-4A69-429B-B759-23F93A851CA0Q33997122-7581697B-3870-4803-865A-74AC5E1BB098Q34064728-8E4F0811-B5CE-4263-ACCB-A9EF5FF98ED7Q34078880-3B5A6118-7AAD-4962-90C1-DB8DCC666A5CQ34202076-229C8F14-792F-4505-BFAC-0A2C456AE134Q34428534-CA40E944-C549-497B-80F9-C71F4D057855Q34581048-0E12FDCF-4B72-4310-A2EF-5EB9202843A6Q34720051-7BF62217-7958-409B-858D-0CF8C3B381D4Q34727416-F342D730-AD69-4BAE-9BFD-B6AB1F76C7B3Q35036343-8D2BF5A4-D2D4-4AC1-9CF1-9BA0A63F2CC9Q35114027-BC37873D-45F2-40C3-9424-7C2BF35501EEQ35309312-61F4230F-0232-438F-AA2E-F26E3B2D41C1Q35405358-DA88B79F-E3DD-4626-A3D6-F3F4CD4B017EQ35670313-2A4BA9F6-49AC-41D6-AA94-4C785B5F60AAQ36387826-255F0D1E-E3EF-4073-8C22-409059C0F970Q36477987-A112931A-9EFE-4932-9151-7042476BC50BQ36591816-D382B2D4-7C13-48CE-A48D-79E65F0C22FEQ36775237-06B265CE-2720-46D9-AEE3-2972EDB8CE43Q36916126-2613CB0F-E145-438B-8DF0-2DC6254C71C3Q36919737-7A3CE4EC-3C04-4A39-9B29-B36E5C2115A4Q36943239-10B57A84-C42A-419D-90B0-2E71AAC6E3AEQ37256080-D0BEA261-A1BC-40EC-941F-54CAD249B185Q37686101-156D9544-8B4C-49BC-BFF6-C7F08DDBA94BQ37703507-10497997-EEA2-42AE-9FD8-FBC3B70AE65FQ37715385-64D38C7A-5CD6-43F5-A869-84B830BA0783Q37978933-3F2E5470-3C9B-430A-884F-1FDA54292235Q38037222-207C8680-2964-4D10-9889-670ADE7DBC9CQ38124640-45C2E68B-7420-442A-8DA9-0CA2B3D9D78BQ38200729-80A63AF6-673B-407C-A271-9121CFE8FE42Q38222238-BCAF247F-6807-434C-A10D-8B5A37671663Q38593136-7ED363E8-018C-4C89-9139-0C6288CCF919Q38599291-B620FC0D-685C-4DDD-A1A2-66F0E6E28303Q39035896-11153763-A97B-4E24-AAC2-55896A996DD3
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Giulio G. Muccioli
@ast
Giulio G. Muccioli
@en
Giulio G. Muccioli
@es
Giulio G. Muccioli
@sl
type
label
Giulio G. Muccioli
@ast
Giulio G. Muccioli
@en
Giulio G. Muccioli
@es
Giulio G. Muccioli
@sl
altLabel
Giulio G. Muccioli
@en
prefLabel
Giulio G. Muccioli
@ast
Giulio G. Muccioli
@en
Giulio G. Muccioli
@es
Giulio G. Muccioli
@sl
P106
P1153
7006941029
P2013
BPBL-research-group-1705367409698776
P21
P2798
P31
P496
0000-0002-1600-9259